Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature.

Skacel, Jan; Melichar, Bohuslav; Mohelnikova-Duchonova, Beatrice; Lemstrova, Radmila

Skacel, Jan; Melichar, Bohuslav; Mohelnikova-Duchonova, Beatrice; Lemstrova, Radmila.

Afiliación

Skacel J; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Zdravotniku 7, 779 00 Olomouc, Czech Republic.
Melichar B; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Zdravotniku 7, 779 00 Olomouc, Czech Republic.
Mohelnikova-Duchonova B; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Zdravotniku 7, 779 00 Olomouc, Czech Republic.
Lemstrova R; Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Zdravotniku 7, 779 00 Olomouc, Czech Republic.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub ; 167(4): 376-384, 2023 Dec.

Article en En | MEDLINE | ID: mdl-35703362

Asunto(s)

Melanoma; Nivolumab; Masculino; Humanos; Persona de Mediana Edad; Ipilimumab/uso terapéutico; Nivolumab/efectos adversos; Melanoma/tratamiento farmacológico; Melanoma/patología; Progresión de la Enfermedad; Taxoides/uso terapéutico

Palabras clave

hyperprogressive disease; ipilimumab; melanoma; nivolumab; paclitaxel

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans / Male / Middle aged Idioma: En Revista: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: República Checa

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google